These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 37503259)
1. Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP. Zhang H; Kafeiti N; Lee S; Masarik K; Zheng H; Zhan H bioRxiv; 2023 Jul; ():. PubMed ID: 37503259 [TBL] [Abstract][Full Text] [Related]
2. Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms. Zhang H; Kafeiti N; Masarik K; Lee S; Yang X; Zheng H; Zhan H Arterioscler Thromb Vasc Biol; 2024 Sep; 44(9):1960-1974. PubMed ID: 38989576 [TBL] [Abstract][Full Text] [Related]
3. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. Castiglione M; Jiang YP; Mazzeo C; Lee S; Chen JS; Kaushansky K; Yin W; Lin RZ; Zheng H; Zhan H J Thromb Haemost; 2020 Dec; 18(12):3359-3370. PubMed ID: 32920974 [TBL] [Abstract][Full Text] [Related]
4. A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm. Zhang H; Yeware A; Lee S; Zhan H Front Oncol; 2021; 11():753465. PubMed ID: 34765558 [TBL] [Abstract][Full Text] [Related]
5. JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment. Mazzeo C; Quan M; Wong H; Castiglione M; Kaushansky K; Zhan H Blood Cells Mol Dis; 2021 Sep; 90():102585. PubMed ID: 34139651 [TBL] [Abstract][Full Text] [Related]
6. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357 [TBL] [Abstract][Full Text] [Related]
7. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells. Kaushansky K; Zhan H Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351 [TBL] [Abstract][Full Text] [Related]
8. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling. Zhang Y; Lin CHS; Kaushansky K; Zhan H Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133 [TBL] [Abstract][Full Text] [Related]
9. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). Dunbar A; Nazir A; Levine R Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953 [TBL] [Abstract][Full Text] [Related]
10. The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms. Zhan H; Lin CHS; Segal Y; Kaushansky K Leukemia; 2018 Feb; 32(2):462-469. PubMed ID: 28744010 [TBL] [Abstract][Full Text] [Related]
11. JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles. Hekimoğlu H; Toprak SF; Sözer S Turk J Haematol; 2022 Feb; 39(1):13-21. PubMed ID: 34981912 [TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center]. Li MY; Chao HY; Sun AN; Qiu HY; Jin ZM; Tang XW; Han Y; Fu CC; Chen SN; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):295-300. PubMed ID: 28468090 [No Abstract] [Full Text] [Related]
13. Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in Wang Y; Ran F; Lin J; Zhang J; Ma D Technol Cancer Res Treat; 2023; 22():15330338231154092. PubMed ID: 36744404 [TBL] [Abstract][Full Text] [Related]
14. [Analysis of CHIP-Related Mutation and Risk of Cardio-Cerebrovasculars Events in Patients with Myeloproliferative Neoplasms]. Han X; Bai BB; Feng CC; Zhao S; Chen Y Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):190-196. PubMed ID: 38387920 [TBL] [Abstract][Full Text] [Related]
15. Circulating CD133+/–CD34– Have Increased c- Uslu Bıçak İ; Tokcan B; Yavuz AS; Tokdemir SS Turk J Haematol; 2023 Feb; 40(1):28-36. PubMed ID: 36458557 [TBL] [Abstract][Full Text] [Related]
16. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027 [TBL] [Abstract][Full Text] [Related]
17. Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke. Chen CC; Hsu CC; Huang CE; Chen YY; Lung J; Ho HY; Li CP; Lee JD Curr Neurovasc Res; 2017; 14(3):222-231. PubMed ID: 28625126 [TBL] [Abstract][Full Text] [Related]
18. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms. Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228 [TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. Spivak JL; Merchant A; Williams DM; Rogers O; Zhao W; Duffield A; Resar LS; Moliterno AR; Zhao ZJ PLoS One; 2020; 15(6):e0232801. PubMed ID: 32479500 [TBL] [Abstract][Full Text] [Related]
20. Functional Consequences of Mutations in Myeloproliferative Neoplasms. Constantinescu SN; Vainchenker W; Levy G; Papadopoulos N Hemasphere; 2021 Jun; 5(6):e578. PubMed ID: 34095761 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]